Bridgeway Capital Management LLC Makes New Investment in iSpecimen Inc. (NASDAQ:ISPC)

Bridgeway Capital Management LLC acquired a new position in shares of iSpecimen Inc. (NASDAQ:ISPC) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 21,800 shares of the company’s stock, valued at approximately $58,000. Bridgeway Capital Management LLC owned about 2.27% of iSpecimen as of its most recent filing with the Securities & Exchange Commission.

iSpecimen Stock Performance

Shares of ISPC stock opened at $1.18 on Wednesday. The stock’s 50-day moving average is $1.26 and its two-hundred day moving average is $2.42. The firm has a market cap of $2.95 million, a price-to-earnings ratio of -0.06 and a beta of 1.73. iSpecimen Inc. has a 1 year low of $1.02 and a 1 year high of $11.80.

iSpecimen (NASDAQ:ISPC) last issued its quarterly earnings data on Monday, April 14th. The company reported ($6.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.00) by ($2.28). The firm had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $2.98 million. iSpecimen had a negative return on equity of 139.25% and a negative net margin of 91.66%.

iSpecimen Profile

iSpecimen Inc provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers.